President Donald Trump’s nominee to head the Food and Drug Administration offers a bolstered resume in the medical field.
Trump recently announced Stephen Hahn of Texas as the nominee to be the next FDA Commissioner.
Hahn has been Chief Medical Executive at The University of Texas MD Anderson Cancer Center in Houston, Texas, since May of 2018.
MDACC is a research-driven patient care organization that has approximately 21,000 employees with an annual revenue of $5 billion and the largest number of clinical trials in the United States.
As a radiation oncologist, Dr. Hahn specializes in treating lung cancer and sarcoma.
Politico reports Hahn offers a sharp contrast from former FDA chief Scott Gottlieb, as Hahn’s last government job was in the 1990s, while Gotleib had a wealth of federal experience when nominated.
The nomination passes over acting commissioner Ned Sharpless, who is the former head of the National Cancer Institute. Hahn must be confirmed by the Senate.